Avalo Therapeutics
(NASDAQ:AVTX)
$11.00
0.16[1.48%]
At close: Jun 14
$11.80
-0.8[-6.78%]
After Hours: 3:14AM EDT
Consensus Rating1
Outperform
Highest Price Target1
$35.00
Lowest Price Target1
$0.75
Consensus Price Target1
$12.92

Avalo Therapeutics (NASDAQ:AVTX) Stock, Analyst Ratings, Price Targets, Predictions

Avalo Therapeutics Inc has a consensus price target of $12.92, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, RBC Capital, and RBC Capital on April 16, 2024, June 27, 2023, and May 10, 2023. With an average price target of $14.92 between Oppenheimer, RBC Capital, and RBC Capital, there's an implied 35.61% upside for Avalo Therapeutics Inc from these 3 analyst ratings.

Analyst Trends and Forecast
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
1.6
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Oppenheimer
RBC Capital
Jefferies

1calculated from analyst ratings

Analyst Ratings for Avalo Therapeutics

Buy NowGet Alert
04/16/2024Buy Now218.18%Oppenheimer
Leland Gershell
→ $35UpgradePerform → OutperformGet Alert
06/27/2023Buy NowOppenheimer
Leland Gershell
DowngradeOutperform → PerformGet Alert
06/27/2023Buy Now-93.18%RBC Capital
Gregory Renza
$2160 → $180DowngradeOutperform → Sector PerformGet Alert
05/10/2023Buy Now-18.18%RBC Capital
Gregory Renza
$4080 → $2160MaintainsOutperformGet Alert
02/08/2023Buy Now-72.73%Jefferies
Chris Howerton
→ $720DowngradeHold → UnderperformGet Alert
03/03/2022Buy Now-93.18%Jefferies
Chris Howerton
$14400 → $2160DowngradeBuy → HoldGet Alert
03/03/2022Buy Now-63.64%RBC Capital
Gregory Renza
$14400 → $11520MaintainsOutperformGet Alert
09/24/2021Buy Now-45.45%RBC Capital
Gregory Renza
→ $17280Initiates → OutperformGet Alert

FAQ

Q

What is the target price for Avalo Therapeutics (AVTX) stock?

A

The latest price target for Avalo Therapeutics (NASDAQ:AVTX) was reported by Oppenheimer on April 16, 2024. The analyst firm set a price target for $35.00 expecting AVTX to rise to within 12 months (a possible 218.18% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Avalo Therapeutics (AVTX)?

A

The latest analyst rating for Avalo Therapeutics (NASDAQ:AVTX) was provided by Oppenheimer, and Avalo Therapeutics upgraded their outperform rating.

Q

When was the last upgrade for Avalo Therapeutics (AVTX)?

A

The last upgrade for Avalo Therapeutics Inc happened on April 16, 2024 when Oppenheimer raised their price target to $35. Oppenheimer previously had a perform for Avalo Therapeutics Inc.

Q

When was the last downgrade for Avalo Therapeutics (AVTX)?

A

The last downgrade for Avalo Therapeutics Inc happened on June 27, 2023 when Oppenheimer changed their price target from N/A to N/A for Avalo Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Avalo Therapeutics (AVTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avalo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avalo Therapeutics was filed on April 16, 2024 so you should expect the next rating to be made available sometime around April 16, 2025.

Q

Is the Analyst Rating Avalo Therapeutics (AVTX) correct?

A

While ratings are subjective and will change, the latest Avalo Therapeutics (AVTX) rating was a upgraded with a price target of $0.00 to $35.00. The current price Avalo Therapeutics (AVTX) is trading at is $11.00, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch